Open AccessAntitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma
Author(s) -
Liang Li,
Yunhong Huang,
Yi Li,
Feng-Qiang Wang,
Bo-Yang Shang,
YongSu Zhen
Publication year - 2005
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v11.i29.4478
Subject(s) - cytotoxicity , monoclonal antibody , mtt assay , collagenase , microbiology and biotechnology , conjugate , clonogenic assay , cancer research , pathology , chemistry , medicine , antibody , biology , in vitro , immunology , biochemistry , mathematical analysis , mathematics , enzyme
Type IV collagenase including MMP-2 and -9 plays an important role in cancer cell invasion and metastasis and is an attractive target for mAb-directed therapy. The immunoreactivity of mAb 3G11, a mAb directed against type IV collagenase in human colorectal carcinomas, was studied by immuno-histochemical (IHC) staining. mAb 3G11 was conjugated to an antitumor antibiotic lidamycin (LDM). The antitumor activity of 3G11-LDM conjugate against colon carcinoma was investigated in mice.